viewAgenus Inc

Agenus shares climb on "best-in-class" phase 3 shingles vaccine study, says H.C. Wainwright


Agenus (NASDAQ:AGEN) shares jumped in early trading Friday after the biotech company and its partner GlaxoSmithKline announced yesterday positive phase 3 data from the HZ/su shingles vaccine program, reducing the risk of shingles by 97.2 percent.

H.C. Wainwright reiterated its buy rating and 12-month price target of $6 on the company.

"We view these results as excellent news for investors, as the shingles vaccine program could potentially yield worldwide revenues surpassing $750 MM, based on the performance of Merck’s approved zoster vaccine (Zostavax)," wrote HCW analyst Reni Benjamin in a note released to investors Friday morning.

"We believe this could translate to a steady stream of royalty revenue for Agenus, potentially peaking between $10 to $20 million per year if HZ/su is approved."

HCW highlighted that the shingles vaccine is just one of 17 ongoing partnered programs involving QS-21, and that HZ/su is the second vaccine to demonstrate efficacy in a randomized phase 3 trial after the RTS,S malaria vaccine.

"In our opinion, potential royalties from multiple QS-21 programs could ultimately offset a significant portion of costs associated with development of Agenus' immuno-oncology pipeline, which currently includes eight fully human antibodies against a variety of checkpoint molecules."

In the phase 3 shingles study, 16,136 adults older than 50 were enrolled in the study, with results showing a 97.2 reduction in risk of contracting shingles in patients receiving the HZ/su vaccine, compared to placebo. The vaccine is based on the gE protein from varicella-zoster virus, formulated with the QS-21 adjuvant.

HCW said the results so far point to "best-in-class efficacy", as Merck's Zostavax vaccine demonstrated a 69.8 percent vaccine efficacy in a phase 3 trial that enrolled 22,439 patients.

Full results from Agenus' trial are expected next year, potentially supporting a BLA application, HCW said, and triggering a milestone payment to Agenus.

"Given its high relative efficacy, we believe HZ/su could be able to match or exceed Zostavax’s peak sales if approved," HCW's Benjamin said.

Agenus has about $46.4 million in cash, and with the potential to secure new partnerships, HCW said it believes Agenus "represents an undervalued player in the immuno-oncology space."

The NYC, NY-based company is focused on the development and commercialization of technologies to treat cancers and infectious diseases. Its shares rose 4.7 percent to US$4.11 in New York as of 10:05am ET, extending year-to-date gains to over 54 percent.

Quick facts: Agenus Inc

Price: 5.18 USD

Market: NASDAQ
Market Cap: $950.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Davide Bosio previews hotly anticipated IPOs for Miramar Resources and Zebit

Davide Bosio from Shaw and Partners says it's been a terrific start to the listing process for Miramar Resources, a junior West Australia exploration company. ''We opened up the offer and closed literally on the same day raising $8mln''. Bosio adds that Zebit is still on track to list on the ASX...

3 days ago

3 min read